Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Early Intravenous Beta-Blockade in Acute Myocardial Infarction

      ,

      Cardiology

      S. Karger AG

      Acute disease, Beta blockade, Myocardial infarction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The clinical effects of early intravenous beta-blockade followed by short-term oral treatment in acute myocardial infarction (MI) have been studied in 30 randomized trials totaling almost 28,000 patients. This treatment reduces the incidence of infarction by 10–15% in patients with threatened MI, reduces infarct size by 20–30%; reduces the incidence of nonfatal reinfarction, nonfatal cardiac arrest and mortality each by about 15 %. Treatment has to start within 12 h of the onset of symptoms to be able to reduce measures of infarct size and infarct development. If patients are carefully selected serious side effects are rare and reversible. Based on the different presumed mechanisms of benefit it would be reasonable to expect the combination of i.v. beta-blockade and other therapies of proven benefit to be more beneficial than either class of agent used alone.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5038-3
          978-3-318-01533-1
          0008-6312
          1421-9751
          1989
          1989
          11 November 2008
          : 76
          : 2
          : 132-143
          Affiliations
          Clinical Trial Branch, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md., USA
          Article
          174484 Cardiology 1989;76:132–143
          10.1159/000174484
          2568179
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 12
          Categories
          Recent Advances in the Management of Patients with Acute Myocardial Infarction

          Comments

          Comment on this article